Quantbot Technologies LP Nuvation Bio Inc. Transaction History

Quantbot Technologies LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 07, 2022	SELL	$0.29 - $4.04 $5,651 - $78,727	-19,487 Reduced 73.16%	7,150 $16,000
Q2 2022 Aug 09, 2022	BUY	$3.24 - $5.85 $42,942 - $77,535	13,254 Added 99.04%	26,637 $86,000
Q1 2022 May 16, 2022	BUY	$4.6 - $8.83 $36,712 - $70,472	7,981 Added 147.74%	13,383 $70,000
Q4 2021 Feb 11, 2022	BUY	$7.75 - $10.05 $41,865 - $54,290	5,402 New	5,402 $45,000
Q3 2021 Nov 09, 2021	SELL	$7.78 - $10.0 $34,971 - $44,950	-4,495 Closed	0 $0
Q2 2021 Aug 12, 2021	BUY	$9.22 - $14.48 $29,310 - $46,031	3,179 Added 241.57%	4,495 $41,000
Q1 2021 May 14, 2021	BUY	$9.0 - $14.57 $11,844 - $19,174	1,316 New	1,316 $13,000

152

123M

9.7K

6.5K

Ticker NUVB
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 217,244,000
Market Cap $480M
Description
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that e...

Get notified when there are updates to the investment portfolio of Quantbot Technologies LP, based on Form 13F filings with the SEC.

Stay updated on Quantbot Technologies LP with notifications on news.